Cilengitide
Recurrent Childhood Brain Tumor
National Cancer Institute (NCI)protein_peptidePhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 43/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Childhood Brain Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Procarbazine National Cancer Institute (NCI) | Phase 2 | BB |
Cediranib National Cancer Institute (NCI) | Phase 2 | B |
Veliparib National Cancer Institute (NCI) | Phase 1 | CC |
Vinorelbine National Cancer Institute (NCI) | Phase 1 | CC |
Ispinesib National Cancer Institute (NCI) | Phase 1 | CC |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 1 | CC |
DEXAMETHASONE National Cancer Institute (NCI) | Phase 1 | CC |
cc-5013 National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Cilengitide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →